Phase II study of panitumumab with FOLFOX or FOLFIRI as 1st line treatment in patients with metastatic colorectal cancer in Japan
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: The investigators choose the treatment A or Barbitrarily. A: FOLFOX + panitumumab B: FOLFIRI + panitumumab Repeat every 14 days until meeting the withdrawal criteria. Primary outcome(s): Overall response rate (ORR) Study Design: Single arm Non-randomized
创建时间：
2011-05-15
